S&P 500   3,960.27 (+0.67%)
DOW   33,719.47 (+0.36%)
QQQ   283.23 (+0.96%)
AAPL   141.98 (+0.74%)
MSFT   246.69 (+0.95%)
META   115.51 (+1.39%)
GOOGL   94.03 (-0.96%)
AMZN   89.79 (+1.50%)
TSLA   172.39 (-0.95%)
NVDA   169.16 (+4.94%)
NIO   13.32 (+5.88%)
BABA   94.02 (+6.44%)
AMD   69.77 (-0.53%)
T   19.12 (-0.93%)
MU   55.14 (+2.45%)
CGC   2.99 (-7.72%)
F   13.11 (+0.08%)
GE   83.24 (-2.07%)
DIS   92.34 (+0.21%)
AMC   6.14 (+1.49%)
PYPL   74.22 (-0.27%)
PFE   51.68 (+2.87%)
NFLX   308.23 (-0.06%)
S&P 500   3,960.27 (+0.67%)
DOW   33,719.47 (+0.36%)
QQQ   283.23 (+0.96%)
AAPL   141.98 (+0.74%)
MSFT   246.69 (+0.95%)
META   115.51 (+1.39%)
GOOGL   94.03 (-0.96%)
AMZN   89.79 (+1.50%)
TSLA   172.39 (-0.95%)
NVDA   169.16 (+4.94%)
NIO   13.32 (+5.88%)
BABA   94.02 (+6.44%)
AMD   69.77 (-0.53%)
T   19.12 (-0.93%)
MU   55.14 (+2.45%)
CGC   2.99 (-7.72%)
F   13.11 (+0.08%)
GE   83.24 (-2.07%)
DIS   92.34 (+0.21%)
AMC   6.14 (+1.49%)
PYPL   74.22 (-0.27%)
PFE   51.68 (+2.87%)
NFLX   308.23 (-0.06%)
S&P 500   3,960.27 (+0.67%)
DOW   33,719.47 (+0.36%)
QQQ   283.23 (+0.96%)
AAPL   141.98 (+0.74%)
MSFT   246.69 (+0.95%)
META   115.51 (+1.39%)
GOOGL   94.03 (-0.96%)
AMZN   89.79 (+1.50%)
TSLA   172.39 (-0.95%)
NVDA   169.16 (+4.94%)
NIO   13.32 (+5.88%)
BABA   94.02 (+6.44%)
AMD   69.77 (-0.53%)
T   19.12 (-0.93%)
MU   55.14 (+2.45%)
CGC   2.99 (-7.72%)
F   13.11 (+0.08%)
GE   83.24 (-2.07%)
DIS   92.34 (+0.21%)
AMC   6.14 (+1.49%)
PYPL   74.22 (-0.27%)
PFE   51.68 (+2.87%)
NFLX   308.23 (-0.06%)
S&P 500   3,960.27 (+0.67%)
DOW   33,719.47 (+0.36%)
QQQ   283.23 (+0.96%)
AAPL   141.98 (+0.74%)
MSFT   246.69 (+0.95%)
META   115.51 (+1.39%)
GOOGL   94.03 (-0.96%)
AMZN   89.79 (+1.50%)
TSLA   172.39 (-0.95%)
NVDA   169.16 (+4.94%)
NIO   13.32 (+5.88%)
BABA   94.02 (+6.44%)
AMD   69.77 (-0.53%)
T   19.12 (-0.93%)
MU   55.14 (+2.45%)
CGC   2.99 (-7.72%)
F   13.11 (+0.08%)
GE   83.24 (-2.07%)
DIS   92.34 (+0.21%)
AMC   6.14 (+1.49%)
PYPL   74.22 (-0.27%)
PFE   51.68 (+2.87%)
NFLX   308.23 (-0.06%)
NASDAQ:KOD

Kodiak Sciences - KOD Stock Forecast, Price & News

$7.29
+0.09 (+1.25%)
(As of 12/8/2022 02:44 PM ET)
Add
Compare
Today's Range
$7.10
$7.38
50-Day Range
$6.52
$8.05
52-Week Range
$4.90
$19.27
Volume
4,077 shs
Average Volume
250,039 shs
Market Capitalization
$381.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.11

Kodiak Sciences MarketRank™ Forecast

Analyst Rating
Hold
2.13 Rating Score
Upside/​Downside
240.7% Upside
$25.11 Price Target
Short Interest
Healthy
5.52% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.92
Upright™ Environmental Score
News Sentiment
0.85mentions of Kodiak Sciences in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($6.52) to ($5.66) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.65 out of 5 stars

Medical Sector

93rd out of 1,027 stocks

Biological Products, Except Diagnostic Industry

12th out of 171 stocks

KOD stock logo

About Kodiak Sciences (NASDAQ:KOD) Stock

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Receive KOD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kodiak Sciences and its competitors with MarketBeat's FREE daily newsletter.

KOD Stock News Headlines

Kodiak Sciences Inc (NASDAQ: KOD)
Kodiak Sciences: Q2 Earnings Insights
Why Kodiak Sciences Stock Is Sharply Lower Today
See More Headlines
Receive KOD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kodiak Sciences and its competitors with MarketBeat's FREE daily newsletter.

KOD Company Calendar

Last Earnings
11/09/2022
Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/07/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KOD
Fax
N/A
Employees
93
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$25.11
High Stock Price Forecast
$75.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+244.5%
Consensus Rating
Hold
Rating Score (0-4)
2.13
Research Coverage
8 Analysts

Profitability

Net Income
$-266,990,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$12.83 per share

Miscellaneous

Free Float
30,025,000
Market Cap
$381.34 million
Optionable
Optionable
Beta
1.78

Key Executives

  • Dr. Victor Perlroth M.D. (Age 49)
    Co-Founder, Chairman, CEO & Pres
    Comp: $1.18M
  • Mr. John A. Borgeson CPAMr. John A. Borgeson CPA (Age 60)
    M.B.A., MBA, CPA, Sr. VP, CFO & Sec.
    Comp: $704.5k
  • Dr. Jason S. Ehrlich M.D. (Age 46)
    Ph.D., Chief Medical Officer & Chief Devel. Officer
    Comp: $779.25k
  • Dr. Michael S. Louie Ph.D.
    Sr. VP of Digital Transformation & Chief Information Officer
  • Dr. Hong Liang (Age 50)
    Sr. VP of Discovery Medicine
  • Ms. Almas Qudrat M.Sc.
    Sr. VP of Quality Operations













KOD Stock - Frequently Asked Questions

Should I buy or sell Kodiak Sciences stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kodiak Sciences in the last year. There are currently 2 sell ratings, 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" KOD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KOD, but not buy additional shares or sell existing shares.
View KOD analyst ratings
or view top-rated stocks.

What is Kodiak Sciences' stock price forecast for 2023?

8 Wall Street research analysts have issued 1 year price objectives for Kodiak Sciences' shares. Their KOD share price forecasts range from $6.00 to $75.00. On average, they anticipate the company's share price to reach $25.11 in the next year. This suggests a possible upside of 245.9% from the stock's current price.
View analysts price targets for KOD
or view top-rated stocks among Wall Street analysts.

How have KOD shares performed in 2022?

Kodiak Sciences' stock was trading at $84.78 on January 1st, 2022. Since then, KOD shares have decreased by 91.4% and is now trading at $7.26.
View the best growth stocks for 2022 here
.

Are investors shorting Kodiak Sciences?

Kodiak Sciences saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 2,720,000 shares, a drop of 10.5% from the October 31st total of 3,040,000 shares. Based on an average trading volume of 377,900 shares, the short-interest ratio is currently 7.2 days. Currently, 5.5% of the company's shares are short sold.
View Kodiak Sciences' Short Interest
.

When is Kodiak Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our KOD earnings forecast
.

How were Kodiak Sciences' earnings last quarter?

Kodiak Sciences Inc. (NASDAQ:KOD) posted its earnings results on Wednesday, November, 9th. The company reported ($1.47) earnings per share for the quarter, beating the consensus estimate of ($1.82) by $0.35.

What other stocks do shareholders of Kodiak Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kodiak Sciences investors own include Quest Diagnostics (DGX), Cronos Group (CRON), Deere & Company (DE), GrowGeneration (GRWG), Immunomedics (IMMU), Teck Resources (TECK), Abbott Laboratories (ABT), Ability (ABIL), AbbVie (ABBV) and

When did Kodiak Sciences IPO?

(KOD) raised $126 million in an initial public offering on Thursday, October 4th 2018. The company issued 9,000,000 shares at a price of $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch acted as the underwriters for the IPO and Barclays and Chardan were co-managers.

What is Kodiak Sciences' stock symbol?

Kodiak Sciences trades on the NASDAQ under the ticker symbol "KOD."

Who are Kodiak Sciences' major shareholders?

Kodiak Sciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.86%), Vanguard Group Inc. (3.15%), State Street Corp (1.87%), Price T Rowe Associates Inc. MD (1.43%), Two Sigma Advisers LP (1.34%) and Federated Hermes Inc. (0.80%). Insiders that own company stock include Bros Advisors Lp Baker, Hong Liang, Jason Ehrlich, John A Borgeson, Richard S Levy and Victor Perlroth.
View institutional ownership trends
.

How do I buy shares of Kodiak Sciences?

Shares of KOD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kodiak Sciences' stock price today?

One share of KOD stock can currently be purchased for approximately $7.26.

How much money does Kodiak Sciences make?

Kodiak Sciences (NASDAQ:KOD) has a market capitalization of $379.77 million. The company earns $-266,990,000.00 in net income (profit) each year or ($6.83) on an earnings per share basis.

How can I contact Kodiak Sciences?

Kodiak Sciences' mailing address is 2631 HANOVER STREET, PALO ALTO CA, 94304. The official website for the company is kodiak.com. The company can be reached via phone at (650) 281-0850 or via email at ir@kodiak.com.

This page (NASDAQ:KOD) was last updated on 12/8/2022 by MarketBeat.com Staff